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Purpose In the 1980s the first results of an early multilevel 
contracture release (MLCR) in patients suffering from pro-
gressive Duchenne muscular dystrophy (DMD) showed a 
positive effect on ambulation. Despite the demonstrated 
positive effects of prolongation of walking this treatment is 
not part of current guidelines. The aim of our study was to 
evaluate the effect of MLCR as well as its combination with 
glucocorticoid (GC) treatment on ambulation. 
Methods Data of all boys (n = 86) with DMD treated in our 
outpatient department were analyzed regarding the treat-
ment and loss of independent ambulation. In all, 23 were 
treated with GC only, ten were operated on, 21 received GC 
and underwent MLCR and 32 received neither of the two 
treatments.
Results The analysis of the loss of independent ambulation 
in our cohort showed a comparable extension of the am-
bulatory period between the GC-treated and MLCR-treated 
boys (p = 0.008 and p = 0.005, respectively). Furthermore, 
an additive effect of both therapies was found; patients with 
DMD who had both treatments were able to walk two years 
longer than those with only one of the two treatment options 
(p<0.001).
Conclusion Standard GC treatment and early MLCR in lower 
limbs have an independent positive effect on prolongation of 
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ambulation in patients with DMD. In our cohort, the combi-
nation of both therapies is significantly more effective than 
each therapy alone. We suggest both should be offered to all 
DMD patients eligible.
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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked 
recessive inherited neuromuscular disease caused by 
mutations in the dystrophin gene leading to progres-
sive muscular dystrophy.1 The first clinical signs are 
delayed motor development, followed by frequent 
falling, the Gower’s manoeuvre and eventually loss of 
ambulation.2
To date, no curative therapy is available for most muta-
tions of the dystrophin gene. Different regimens of steroid 
intakes are currently the main component of drug therapy 
for DMD.1,3 Glucocorticoid (GC) medication for DMD has 
numerous effects: preserving muscular function, thereby 
prolonging ambulation, respiratory function and slowing 
down the development of scoliosis.1 Contractures and 
consecutive skeletal deformities have an impact on ambu-
lation at an early stage of the disease.
In 1983, Rideau et al4 published results of an early mul-
tilevel contracture release (MLCR) in Duchenne patients 
showing a positive effect on ambulation which was rein-
forced by Forst and Forst.2,5 Despite the proven positive 
effects of prolongation of walking up to two years after 
MLCR, the procedure is not part of current international 
guidelines.1,6
The aim of our study was twofold: to assess the influ-
ence of our regime of MLCR on ambulation and to check 
whether the combination of surgery and GC treatment 
could enhance the described positive effects.
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Patients and methods
The DMD patient cohort treated in our outpatient clinic 
between 2013 and 2017 was analyzed retrospectively. 
Included were all boys with genetically proven DMD who 
were diagnosed and treated at our institution, thereby 
ensuring only ambulatory boys were in the cohort. All 
ambulatory patients were offered steroid treatment (0.9 
mg/kg body weight (BW) deflazacort or 0.75 mg/kg BW 
prednisolone). All patients received non-standardized 
physiotherapy.
All patients with incipient contractures of the hip, knee 
and ankle joints and/or shortening of the iliotibial band 
were offered MLCR if certain prerequisites were met.2 
These prerequisites were sufficient quadriceps strength 
defined as a total muscle power of at least 3/5 on the 
muscle power scale (Medical Research Council, MRC) and 
being able to rise from a supine position to standing in 
less than 5 seconds.2 The MLCR includes a release of the 
spina muscles (sartorius muscle, tensor fasciae latae mus-
cle, both heads of the rectus femoris muscle), resection of 
the gluteal fascia, complete aponeurectomy of the iliotib-
ial band, tenotomy of the medial hamstrings, chevron-like 
fasciotomy of the lateral hamstrings, lengthening of the 
Achilles tendon and transfer of the tibialis muscle poste-
rior if necessary.2
Postoperatively, below-knee soft casts were applied for 
two weeks. The boys were mobilized out of bed on the 
first postoperative day. They received intensive inpatient 
or outpatient physiotherapy for four to six weeks. None 
of them was treated with splints or orthoses after surgery.
The patient cohort was divided in four groups with 
regard to the treatment: 23 boys had been treated with 
GC medication (GC only group), in ten patients a MLCR 
had been performed (MLCR group), 21 boys had been 
treated with GC medication and MLCR (MLCR+GC group) 
and in 32 both treatments were declined (no treatment). 
As soon as the diagnosis is confirmed the parents are 
acquainted with the treatment options in an interdisciplin-
ary clinic (paediatric neurologist, paediatric orthopaedic 
surgeon, physiotherapist, social worker). The individual 
therapy regime was decided by the parents after a detailed 
consultation with the paediatric neurologist as well as the 
paediatric orthopaedic surgeon.
Kaplan Meier curves were generated for the different 
groups to evaluate the loss of ambulation. Loss of ambu-
lation was defined as loss of the ability to walk more than 
10 metres independently. Differences between the groups 
were tested for significance using the log rank test. To take 
into consideration the alpha-error changes due to multi-
ple testing, the Bonferroni-Holm correction was applied. 
Results
In total, 86 patients with confirmed DMD were included 
in this analysis. Their mean age at last follow-up was 16.2 
Fig. 1 Loss of the ability to ambulate with regard to therapy in patients with Duchenne muscular dystrophy (GC, glucocorticoid; 
MLCR, multilevel contracture release).
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years (sd 8.4). Out of the 86 boys 23 (27%) had been 
treated with GC only. Ten patients (12%) had a MLCR 
according to Rideau 2,4,5 at a mean age of 7.0 years (sd 
1.7). In total, 21 boys (24%) received GC and underwent 
contracture release, while 32 patients (37%) received 
neither of the two treatments. The Kaplan-Meier survival 
curves are shown in Figure 1.
Patients having received neither GC treatment nor 
MLCR lost ambulation at a mean age of 9.6 years (sd 
0.28; 95% confidence interval (CI) 9.0 to 10.1). Patients 
on GC medication were able to walk up until a mean age 
of 11.2 years (sd 0.6; 95% CI 10.0 to 12.5) which is sig-
nificantly longer than without drug or surgical treatment 
(p = 0.009). Patients who received MLCR lost ambulation 
at a mean age of 11.1 years (sd 0.7; 95% CI 9.8 to 12.4) 
which is also longer than without any of the two therapies, 
but not significantly after Bonferroni-Holm alpha-error 
correction (p = 0.066). Patients with the combined treat-
ment of GC medication and surgery were able to walk 
independently up to an age of 14.9 years (sd 1.2; 95% 
CI 13.5 to 18.3) which is significantly longer than with no 
therapy (p < 0.001) as with only one of the two (versus GC 
only p = 0.008; versus MLCR only p = 0.005).
Discussion
Our retrospective study of 86 patients with DMD for 
whom the parents decided about the therapy confirms the 
positive effect of the combination of MLCR and GC medi-
cation on ambulation in DMD patients.2,4,5,7-9 Although we 
were able to include 86 patients in our cohort of this rare 
disease, the subgroups were small and differed in size. 
The early appointments at our institution gave the oppor-
tunity to counsel parents and carers about the treatment 
options from the beginning. Nevertheless, the decision 
making by the parents (proxy) could create bias, which we 
tried to minimize by offering all treatment options to all 
patient eligible. It seemed the only kind of allocation given 
the ethical presumptions by randomization. The end point 
of the loss of ambulation was chosen because so far there 
are no uniform recommendations and it seemed feasible.
The analysis of the loss of independent ambulation in 
our cohort showed a comparable extension of the ambu-
latory period between the GC-treated and MLCR-treated 
boys. Interestingly, not only could we replicate both the 
positive effects of GC treatment and lower limb surgery as 
single treatments but show an additive effect on ambula-
tion by combining both treatment options. Despite this, 
the MLCR is regarded with reservations. One concern 
expressed by some authors is the acceleration of the loss 
of ambulation following MLCR.1,6,10 However, this is less 
likely to occur if the published functional prerequisites 
are followed.2,4 These are valid criteria to define the early 
ambulatory stage. By applying these concise function 
tests it is possible to avoid the above mentioned negative 
surgical outcomes in the majority of cases as the analysis 
of our cohort reveals.
The correct time of surgery is the first step to appraise the 
results regarding MLCR. The second one is the adherence 
to all steps of MLCR to prolong the ambulation of DMD 
patients. The idea of MLCR according to Rideau et al4 is to 
release the antagonists of the antigravity muscles to pro-
vide the latter with the possibility to work effectively despite 
decreasing strength. Hence, it seems quite predictable that 
this effect cannot be achieved if the muscles have already 
become too weak or the limb girdle was not addressed in 
patients with DMD which is well known to start on the pel-
vic level. Thus, the studies presenting negative results after 
MLCR either included patients who passed the early stage 
of ambulation6,10,11,12 or did not adhere completely to the 
pathoanatomical concepts of Rideau et al.1,6,10,13
GC treatment on the other hand is a well-accepted 
symptomatic therapy for DMD which is included in the 
major treatment guidelines.3,14 This is probably due to the 
better evidence when compared with MLCR.3 Despite the 
advantages of the GC medication, the adverse effects – 
weight gain, hypertonia, behavioural changes and osteo-
penia14 – deter quite a few families from this treatment.
Little evidence exists for the positive effects of the ubiq-
uitous stretching therapy as well as orthotics.15
Thus, there exists a number of more or less validated, 
non-curative options to supply the families’ need for treat-
ment. All of them should be provided to patients and par-
ents until a curative therapy is available.
So far, it could not be proved that patients after MLCR 
developed less severe contractures than patients who 
were not operated on. Due to the prolongation of ambu-
lation by GC as well as lower limb surgery according to 
Rideau et al 4 it seems feasible to assume that the latter has 
the potential to have a similar effect. This point, as well as 
the precise analysis of the functional changes after MLCR, 
should be the aim of future investigations.
Conclusion
Standard GC treatment and early MLCR in lower limbs 
have an independent and positive effect on prolongation 
of ambulation in DMD patients. The combination of both 
therapies is significantly more effective than each single 
therapy. To our knowledge, this is the first evidence for a 
significant positive effect of combining GC treatment with 
early multilevel contracture release in order to prolong 
ambulation in DMD patients. Therefore, in our opinion 
early MLCR should be offered to all DMD patients eligible 
and its inclusion in the major treatment guidelines should 
be considered.
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